Palutini (  Baricitinib ) 

Palutini (  Baricitinib )  is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) and JAK2  for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. JAKs are ritical components of signaling mechanisms utilized by a number of cytokines and growth factors, including those that are elevated in rheumatoid arthritis (RA) patients. JAK inhibitors have shown long-term efficacy in RA trials with an early onset of action.